The University of Rochester (UR) Infectious Diseases Division (IDD) has meaningfully contributed to the NIAID HIV/AIDS Clinical Research Networks (CRNs) for over 30 years. The enduring mission of the UR Clinical Trials Unit (CTU) is to support and conduct clinical research on HIV/AIDS that contributes to the discovery of a preventive vaccine for HIV, as well as to the discovery of a cure for HIV, and of treatments that reduce the burden of disease due to HIV infection and its complications. It will acheive this mission by providing exceptional scientific and administrative leadership, and outstanding clinical trials infrastructure, and by engaging with all relevant stakeholders and communities, to ensure that the research it conducts is responsive to community needs.
Five aims are proposed. The first is to strengthen our well-established Clinical Research Sites (CRSs). To do this, we will support 2 domestic CRSs that will participate in the following NIAID CRNs: (i) the `AIDS Clinical Trials Group' (ACTG); and (ii) the `HIV Vaccine Trials Network' (HVTN). We will also develop a plan to diversify UR CTU leadership, and to enhance integration and coordination of these CRSs.
The second aim i s to provide exceptional administrative leadership that accelerates and enhances NIAID clinical research. We will do this by continuing and enhancing effective financial management procedures and a robust quality management program, and by continuously assessing well-defined metrics of operational performance and capacity; these measures will be used to determine improvement opportunities that will be addressed by targeted actions and follow-up evaluation to assess the efficacy of such interventions. Performance data will be coupled to resource allocation, and poorly performing CTU components will be terminated, if necessary.
The third aim i s to provide exceptional scientific leadership that promotes important contributions to the advancement of HIV/AIDS science, and mentors the next generation of CTU researchers. The CTU will oversee and coordinate groundbreaking research activities at the participating CRSs, develop and execute a strong research agenda for the ACTG and HVTN, mentor and train the next generation of CTU researchers, and draw upon campus-wide intellectual capital.
Aim four will provide outstanding clinical trials infrastructure, including data and quality management, regulatory support, laboratory, pharmacy and other resources. Innovations will include procedures that facilitate flexibility and surge capacity, allowing a rapid response to emerging Network needs, as well as shared resources that promote cost efficiency. Finally, our fifth aim is to communicate and engage effectively with all UR CTU stakeholders. The Rochester Community Advisory Board (CAB) and our diverse Community Education and Recruitment (CER) Team will engage with local communities, to increase community awareness and education, and facilitate recruitment and retention of research participants. Finally, we will also continue highly responsive communication and engagement with NIAID, its CRNs, and all other key constituencies.
The enduring mission of the University of Rochester (UR) Clinical Trials Unit (CTU) is to support and conduct clinical research on HIV/AIDS that contributes to the discovery of a preventive vaccine for HIV, as well as to the discovery of a cure for HIV, and of treatments that reduce the burden of disease due to HIV infection and its complications. The UR CTU will acheive this mission by providing exceptional scientific and administrative leadership, together with outstanding clinical trials infrastructure. It will also engage with the communities that it serves, thereby ensuring that the research it conducts is responsive to community needs.
|Martin, Maureen P; Naranbhai, Vivek; Shea, Patrick R et al. (2018) Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1. J Clin Invest 128:1903-1912|
|Ocque, Andrew J; Hagler, Colleen E; Morse, Gene D et al. (2018) Development and validation of an LC-MS/MS assay for tenofovir and tenofovir alafenamide in human plasma and cerebrospinal fluid. J Pharm Biomed Anal 156:163-169|
|Haas, David W; Bradford, Yuki; Verma, Anurag et al. (2018) Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events. Pharmacogenet Genomics 28:179-187|
|Venuto, Charles S; Lim, Jihoon; Messing, Susan et al. (2018) Inflammation investigated as a source of pharmacokinetic variability of atazanavir in AIDS Clinical Trials Group protocol A5224s. Antivir Ther 23:345-351|
|Benson, Constance A; Andersen, Janet W; Macatangay, Bernard J C et al. (2018) Safety and Immunogenicity of Zoster Vaccine Live in Human Immunodeficiency Virus-Infected Adults With CD4+ Cell Counts >200 Cells/mL Virologically Suppressed on Antiretroviral Therapy. Clin Infect Dis 67:1712-1719|
|Li, Binglan; Verma, Shefali S; Veturi, Yogasudha C et al. (2018) Evaluation of PrediXcan for prioritizing GWAS associations and predicting gene expression. Pac Symp Biocomput 23:448-459|
|Riddler, Sharon A; Zheng, Lu; Durand, Christine M et al. (2018) Randomized Clinical Trial to Assess the Impact of the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 on HIV-1 Persistence in Individuals on Effective ART. Open Forum Infect Dis 5:ofy242|
|Elizaga, Marnie L; Li, Shuying S; Kochar, Nidhi K et al. (2018) Safety and tolerability of HIV-1 multiantigen pDNA vaccine given with IL-12 plasmid DNA via electroporation, boosted with a recombinant vesicular stomatitis virus HIV Gag vaccine in healthy volunteers in a randomized, controlled clinical trial. PLoS One 13:e0202753|
|Kalayjian, Robert C; Albert, Jeffrey M; Cremers, Serge et al. (2018) Women have enhanced bone loss associated with phosphaturia and CD4+ cell restoration during initial antiretroviral therapy. AIDS 32:2517-2524|
|Venuto, Charles S; Talal, Andrew H (2017) Intrahepatic Sampling for the Elucidation of Antiviral Clinical Pharmacology. Clin Pharmacol Drug Dev 6:169-175|
Showing the most recent 10 out of 110 publications